Frontline Doctors and Hydroxychloroquine

Hydroxychloroquine Treatment Protocols

Hydroxychloroquine is part of the Zelenko treatment protocol and the FLCCC I-MASK+ treatment protocol for COVID-19. For details, click on the links above.

Hydroxychloroquine (HCQ) is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies.

As of June 2022 there have been more than 30 studies of Hydroxychloroquine for early treatment with an overall average improvement of 64% as compared to the control groups.

Here’s a chart from c19early.com that shows that hydroxychloroquine performs better than ivermectin when given as early treatment in terms of risk reduction of dying from COVID-19:


The overall improvement for hydroxychloroquine is better than ivermectin (for early treatment); 72 % vs 43 % in terms of death rate. Importantly, hydroxychloroquine needs to be given 'early'.

The evidence tracking on Hydroxychloroquine versus COVID-19 is available at c19hcq.com (constantly updated).

Hydroxychloroquine Map

Below are the US map and the world map which show how difficult or easy it is to obtain HCQ throughout the world. (Source)

Comments

Popular posts from this blog

Dr Peter McCullough Early Treatment Protocol 2022

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (July 2022)

America's Frontline Doctors Early Treatment Protocol and Contact a Physician 2022

How to Make Povidone Iodine 1% Nasal Spray

FLCCC I-CARE COVID Treatment Protocol for Outpatients 2022

Quercetin and Zinc: Zelenko Treatment Protocol (2022)

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments

Dr Peter McCullough: Nasal Spray and Mouth Gargle to stop COVID?

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (July 2022)

Paxlovid vs Monoclonal Antibodies: Effective against Omicron?